Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from EMvision Medical Devices Ltd. ( (AU:EMV) ).
S&P Dow Jones Indices has announced changes to its S&P/ASX equity benchmarks following the March quarterly review, reshaping the composition of the main Australian indices across the large-, mid-, and small-cap segments. The rebalance reflects shifts in market capitalisation and sector performance, and will take effect before trading opens on March 23, 2026.
Northern Star Resources will enter the blue-chip S&P/ASX 20 at the expense of Santos, while Light & Wonder and PLS Group join the S&P/ASX 50 as Seek and Technology One exit. The reshuffle cascades through the S&P/ASX 100, 200 and 300, adding several resources, energy transition and specialist companies, with multiple financials, infrastructure and selected industrial names being removed, which may drive portfolio adjustments by index-tracking and benchmark-aware investors.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$3.15 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
More about EMvision Medical Devices Ltd.
Average Trading Volume: 35,263
Technical Sentiment Signal: Sell
Current Market Cap: A$159.9M
For detailed information about EMV stock, go to TipRanks’ Stock Analysis page.